Bioverativ Inc buy stratec
Start price
22.01.18
/
50%
€93.98
Target price
22.01.18
€90.20
Performance (%)
-0.04%
End price
22.01.18
€93.94
Summary
This prediction ended on 22.01.18 with a price of €93.94. During the runtime of the prediction for Bioverativ Inc the price only changed by -0.04%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bioverativ Inc | - | - | - | - |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% | 52.377% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% | 72.449% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% | 57.579% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% | 62.154% |
Comments by stratec for this prediction
In the thread Bioverativ Inc diskutieren
stratec stimmt der Buy-Einschätzung von zeckenjoe zu
- Sanofi (NYSE:SNY) is close to acquiring Bioverativ (NASDAQ:BIVV) for $105 a share, valuing the hemophilia drug maker - separated from Biogen (NASDAQ:BIIB) last year - at about $11.6B, according to multiple reports.
- Sanofi
expects the purchase to be immediately accretive to its EPS in the 2018
full financial year, up to 5% accretive for the following year and
achieve a ROIC in excess of the cost of capital before 2021. - Update: In a press release, Sanofi confirmed that it will acquire Bioverativ for $11.6B. BIVV is up 62% premarket on modest volume. SNY is down 3% on average volume.
(Vom Mitglied beendet)